子宮內膜症：更進一步創新目標和必要的新型治療法投入市場 是由出版商Datamonitor在2009年12月所出版的。
這份英文市場調查報告書包含Pages: 147 價格從美金11400起跳。
現在,世界7大市場的1700萬女性患有子宮內膜症。從這個複雜的症狀很難診斷出來，且原因不明阻礙治療法的發現。
報告書內容包括﹕資工內膜症的症狀和診斷、治療法和潛在性相關分析、進行研究開發企業的戰略、世界7大市場到2018年的市場動向、後期開發階段藥劑的商業性、臨床評價的統整。概要內容如下﹕
概要
摘要
第1章 通路概要和動向
- 主要的調查結果
- 通路概要
- 子宮内膜症相關通路的主要企業
- 主要的研究開發戰略
第2章 子宮内膜症：市場的潛在性
- 主要的調查結果
- 定義
- 患者區分市場
- 流行病學
- 現在的治療法
- 治療指導目標
- 現在的黄金定律
- 現在和將來的7大市場概要
- 市場的定義
- 持續擴大到2018年
- 美國雖為最大市場,但日本為最快速成長市場
- 到2018年,子宮内膜症治療的先驅為口服單相避妊藥
- 商標動向：因為後發藥的滲透，商標藥品本身地位持續下滑
- 其他的市場動向
- 世界的子宮内膜症市場的成長緩慢
- 其他市場在2008年的世界市場佔市場24.3％
- 其他市場在量的方面凌駕7大市場
- 加拿大在2007∼2008年有很大的成長，BRIC各國也在2004∼2008年大幅擴大
- 子宮内膜症的潛在性需求
- 非侵襲性診斷工具
- 患者和醫師的認知提升
- 更優良藥劑
- 以非荷爾蒙劑作代替治療
- 更多資金
- 目標產品專業檔案和現在達成的水準
第3章 研究開發方法
第4章 通路分析和預測
- 主要的調查結果
- 概要
- Visanne
- Elagolix
- 其他的開發中藥劑
- 最近被中止的後期開發化合物
第5章 創新的早期研究
- 主要的調查結果
- 創新的通路
- 血管新生阻礙
- 抗炎症性藥劑
- 17-beta hydroxylase
- 將來的治療
參考資訊
附錄
圖表
Abstract
Introduction
Endometriosis is a common yet poorly understood gynecological disease that
affects women of reproductive age. Symptoms include severe chronic pelvic pain
and infertility. Endometriosis affects over 17 million women across the seven
major markets. Nonetheless, its complex symptomatology contributes to
difficult diagnosis and unclear etiology obstructs the discovery of disease
modifying approaches.
Scope of this research
- Analysis of endometriosis etiology, symptomology, diagnosis, treatment,
prevalence trends, and key unmet market needs.
- Review of the pre-clinical and clinical pipeline for new endometriosis
therapies, including analysis of key R&D company strategies.
- In depth analysis of historic (200408) seven major markets and rest of the
world trends with future (20092018) seven major market dynamics.
- Commercial and clinical assessment of key late-stage pipeline drugs, with
opinion leader comment and region-specific sales forecasts to 2018.
Research and analysis highlights
Environmental factors, increased awareness and diagnosis will cause the
incidence of endometriosis to increase in the seven major markets. Drugs in
the market are not curative and do not provide long term pain relief yet there
are only 13 agents in clinical development for the potential treatment of
endometriosis.
Although contraceptives and progestogens are commonly used to treat
endometriosis, these are mainly used off label. Bayer Schering will be able to
use its sales and marketing resource to overcome the challenging task of
convincing physicians to use its new endometriosis specific drug Visanne
(dienogest) over other hormonal contraceptives.
Neurocrine' s elagolix is the first oral non peptide gonadotropin releasing
hormone (GnRH) antagonist. Phase II trials have shown that it is effective in
treating endometriosis and does not reduce bone mineral density during 6
months therapy. This will allow the drug to become market leading in 2018.
Key reasons to purchase this research
- Analyze competitive environment at time of product launch.
- Validate internal forecasts and market potential for pipeline products.
- Identify licensing opportunities based on company portfolio and market
needs.
Table of Contents
OVERVIEW
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the endometriosis market
- Datamonitor pipeline assessment summary
- Related reports
1. PIPELINE OVERVIEW AND DYNAMICS
- Key findings
- Pipeline overview
- Endometriosis research goals
- Late-stage clinical endometriosis pipeline
- Datamonitor pipeline assessment summary
- Key companies involved in the endometriosis pipeline
- Bayer Schering - women' s health market leader
- Key R&D company strategies
2. ENDOMETRIOSIS - MARKET POTENTIAL
- Key findings
- Definition
- Dynamic progression of endometriosis
- Recurrence in endometriosis
- Etiology
- Symptoms
- Risk factors
- Diagnosis
- Patient segmentation
- Epidemiology
- Seven major markets
- Rest of the world
- Current treatment options
- Treatment guidelines
- Current gold standard
- Lupron (leuprolide acetate, Abbott)
- Current and future seven major market overview
- Endometriosis market definition
- Seven major markets dynamics - endometriosis market will grow up to 2018
- Regional dynamics - the US remains the largest market but Japan is the
fastest growing.
- Class dynamics - oral monophase contraceptives will remain market
leaders for endometriosis treatment in 2018
- Brand dynamics - key brands to lose leading status following generic
incursion
- Rest of the world snapshot
- The global endometriosis market displays weak growth
- The rest of the world accounted for 24.3% of the global market in 2008
- The rest of the world outstrips the seven major markets in terms of
volume
- Canada shows strong growth between 2007 and 2008 but BRIC grows more
between 2004 and 2008
- Unmet need in endometriosis
- Need for a non invasive diagnostic tool
- Need to raise awareness both in the population and among physicians
- Need for better drugs
- Need for nonhormonal drugs as alternative treatments
- Need for increased funding in the disease
- Target product profile versus current level of attainment
3. R&D APPROACH
- Key findings
- Clinical trial design in endometriosis
- Patient inclusion
- Clinical trial size
- Placebo versus active control
- Trial endpoints in endometriosis
4. PIPELINE ANALYSIS & FORECASTS
- Key findings
- Overview
- Pipeline summary
- Comparative forecasts
- Visanne (dienogest; Bayer Schering)
- Drug overview
- Drug profile
- SWOT analysis
- Clinical trial data
- Datamonitor drug assessment for Visanne
- Forecasts to 2018
- Elagolix (NBI-56418; Neurocrine)
- Drug overview
- Drug profile
- SWOT analysis
- Clinical trial data
- Datamonitor drug assessment for elagolix
- Forecasts to 2018
- Other drugs in development for the treatment of endometriosis
- Tanezumab (PF-04383119; Pfizer)
- Femathina (MPI-674; Meditrina)
- Cetrorelix (AEterna Zentaris)
- Late-stage development compounds recently discontinued
- Antiprogestogen development should be further investigated
5. INNOVATIVE EARLY-STAGE APPROACHES
- Key findings
- Innovative stage pipeline for endometriosis
- Blocking angiogenesis
- Leptin receptor antagonist (Cancer Research Technology)
- Anti-inflammatory drugs
- DXL-1215 (InNexus Biotechnology)
- 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD)
- HSD inhibitor (QuatRx Pharmaceuticals)
- The future of treatment in endometriosis
- Genetic profiling will increase prevention of endometriosis
- Increased incidence will drive an improvement in research leading to
improved treatments
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- Conferences attended
APPENDIX
- Methodology
- Market sizing methodology
- Datamonitor forecast methodology
TABLES
- Table: R&D drug pipeline for endometriosis, 2009
- Table: Endometriosis risk factors
- Table: Diagnostic experience with endometriosis according to the type of
physician seen first
- Table: Endometriosis differential diagnosis
- Table: Prevalence of endometriosis across the seven major markets, 2009
- Table: Trends in the prevalence of endometriosis across the seven major
markets (000s), 2009 - 2018
- Table: Prevalence of endometriosis in women affected by chronic pelvic
pain across the seven major markets, 2009
- Table: Trends in the prevalence of endometriosis in women affected by
chronic pelvic pain across the seven major markets (000s), 2009 - 2018
- Table: Prevalence of endometriosis in infertile women across the seven
major markets, 2009
- Table: Trends in the prevalence of endometriosis in infertile women across
the seven major markets (000s), 2009 - 2018
- Table: Prevalence of endometriosis in Australia and Canada, 2009
- Table: Trends in the prevalence of endometriosis in Australia and Canada
(000s), 2009 - 2018
- Table: Prevalence of endometriosis in the BRIC countries, 2009
- Table: Trends in the prevalence of endometriosis in the BRIC countries
(000s), 2009 - 2018
- Table: Drugs approved for the treatment of endometriosis in the seven
major markets, 2009
- Table: Lupron ( leuprolide acetate - drug profile, 2009
- Table: Lupron (leuprolide acetate, Abbott) side-effect profile in
endometriosis patients
- Table: Lupron (leuprolide acetate, Abbott) effect on bone mineral density
in patients with endometriosis
- Table: ICD-10 codes used to define the endometriosis market
- Table: Seven major market sales ($m) dynamics of the endometriosis market,
2004 - 2018
- Table: Seven major market sales ($m) for endometriosis by ATC class, 2004
- 2018
- Table: Seven major market sales ($m) for key brands in endometriosis
treatment, 2004 - 2018
- Table: Global sales ($m) dynamics of the endometriosis market, 2004 - 08
- Table: Global endometriosis market sales ($m) split by region, 2004 - 08
- Table: Key biomarkers investigated for the diagnosis of endometriosis, 2009
- Table: Endometriosis support groups across the seven major markets, 2009
- Table: Summary of pharmacotherapy side effects in endometriosis
- Table: Ability of Lupron (leuprolide, Abbott) to meet unmet needs in
endometriosis in the seven major markets, 2009
- Table: Endpoints for endometriosis trials
- Table: Summary of the Initiative on Methods, Measurements and Pain
Assessments in Clinical Trials (IMMPACT) recommendations
- Table: Endometriosis severity profile scoring system based upon the
Biberoglu and Behrman Scale (1981)
- Table: Summary of studies showing endometriosis effect on quality of life,
2009
- Table: Key products in late-stage R&D pipeline for endometriosis, 2009
- Table: Sales forecasts for key drugs in late-stage development for
endometriosis in the seven major markets, 2009 - 2018 ($m)
- Table: Forecast assumptions for key products in late-stage development for
endometriosis across the seven major markets, 2009 - 2018
- Table: Visanne (dienogest) - drug profile, 2009
- Table: Summary of key clinical trials for Visanne (dienogest)
- Table: Datamonitor drug assessment summary of Visanne (dienogest, Bayer
Schering) for endometriosis, 2009
- Table: Receptor selectivity of various progestins
- Table: Sales forecasts for Visanne in endometriosis in the seven major
markets, 2009 - 2018 ($m)
- Table: Impacting factors on the revenues of Visanne in endometriosis, 2009
- 2018
- Table: Elagolix - drug profile, 2009
- Table: Elagolix: summary of key clinical trials
- Table: Elagolix: Petal-702 study primary endpoint - preliminary results
- Table: Elagolix: Petal-603 study primary endpoint - final results
- Table: Elagolix: Phase II Tulip Petal study - key facts
- Table: Datamonitor drug assessment summary of elagolix (Neurocrine) for
endometriosis, 2009
- Table: Elagolix: bone safety determined in the Petal-603 clinical trial
- Table: Sales forecasts for elagolix in endometriosis in the seven major
markets, 2009 - 2018 ($m)
- Table: Impacting factors on the revenues of elagolix in endometriosis,
2009 - 2018
- Table: Recently discontinued projects in endometriosis
- Table: Preclinical pipeline for the treatment of endometriosis, 2009
- Table: Rest of the world diagnostic value application
- Table: Datamonitor drug assessment scorecard for late stage endometriosis
drugs, 2009
FIGURES
- Figure: Datamonitor endometriosis pipeline assessment summary, 2009
- Figure: Endometriosis clinical pipeline by development stage, 2009
- Figure: Endometriosis clinical pipeline by target, 2009
- Figure: Endometriosis clinical pipeline by mode of administration, 2009
- Figure: Datamonitor endometriosis pipeline assessment summary, 2009
- Figure: Bayer Schering genitourinary therapy area sales performance ($m),
2004 - 08
- Figure: Common endometrial lesion sites
- Figure: Anatomy of retrograde menstruation
- Figure: Endometriosis breakdown of symptoms
- Figure: American Academy Family Physicians (AAFP) endometriosis treatment
guidelines
- Figure: European Society of Human Reproduction and Embryology (ESHRE)
endometriosis treatment guidelines
- Figure: Sales performance of Lupron (leuprolide, TAP Pharmaceutical) in
endometriosis across the seven major markets, 2004 - 2018
- Figure: Endometriosis market sales ($m) across the seven major markets,
2004 - 2018
- Figure: Endometriosis market volume sales (IMS standard units sold) across
the seven major markets, 2004 - 2018
- Figure: Regional endometriosis market value sales ($m) in the across the
seven major markets, 2004 - 08
- Figure: Regional endometriosis market value sales ($m) in the across the
seven major markets, 2008 - 2018
- Figure: Seven major markets endometriosis-specific sales ($m) by ATC
class, 2004 - 2018
- Figure: Seven major market sales ($m) for key brands in endometriosis
treatment, 2004 - 2018
- Figure: Global endometriosis market sales value by region, 2004 - 08
- Figure: Global hormonal endometriosis sales ($m) dynamics, 2004 - 08
- Figure: Global endometriosis market volume (IMS standard units sold) and
value ($) sales by region, 2008
- Figure: Rest of the World endometriosis market sales value ($m), 2004 - 08
- Figure: Rest of the world endometriosis regional market dynamics ($m),
2004 - 08
- Figure: Unmet needs in endometriosis, 2009
- Figure: Datamonitor endometriosis pipeline assessment summary, 2009
- Figure: Visanne (dienogest; Bayer Schering) SWOT analysis, 2009
- Figure: Datamonitor drug assessment summary of Visanne (dienogest, Bayer
Schering) for endometriosis, 2009
- Figure: Sales forecasts for Visanne (dienogest, Bayer Schering) in
endometriosis in the seven major markets, 2009 - 2018 ($m)
- Figure: Elagolix (Neurocrine) SWOT analysis, 2009
- Figure: Datamonitor drug assessment summary of elagolix (Neurocrine) for
endometriosis, 2009
- Figure: Sales forecasts for elagolix (Neurocrine) in endometriosis in the
seven major markets ($m), 2014 - 18
|
